Hepatic ACSL4 levels are elevated in patients with non-alcoholic fatty liver disease, and suppression of hepatic ACSL4 reduces hepatic lipid accumulation by promoting mitochondrial respiration and β-oxidation of fatty acids [35]. The gene discussed is ACSL4; the disease is metabolic dysfunction-associated steatotic liver disease.